NASDAQ:BOLT Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $4.91 -0.15 (-2.96%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$4.96 +0.05 (+1.12%) As of 11/20/2026 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Bolt Biotherapeutics Stock (NASDAQ:BOLT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bolt Biotherapeutics alerts:Sign Up Key Stats Today's Range$4.87▼$5.2150-Day Range$3.35▼$6.5952-Week Range$3.10▼$7.78Volume60,466 shsAverage Volume759,403 shsMarket Capitalization$12.82 millionP/E RatioN/ADividend YieldN/APrice Target$14.50Consensus RatingHold Company Overview Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer. The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors. Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate. The company’s programs are in clinical development, and its therapies are not established treatments for cancer.AI Generated. May Contain Errors. Read More Bolt Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreBOLT MarketRank™: 3.22139652271 of 5 starsBolt Biotherapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 253rd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingBolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBolt Biotherapeutics has a consensus price target of $14.50, representing about 195.3% upside from its current price of $4.91.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Bolt Biotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.72% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently increased by 200.82%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.88 News SentimentBolt Biotherapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Bolt Biotherapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for BOLT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $500,563.00 in company stock, which represents 3.9060% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have bought 389.97% more of their company's stock than they have sold. Specifically, they have bought $628,924.00 in company stock and sold $128,361.00 in company stock.Percentage Held by Insiders9.40% of the stock of Bolt Biotherapeutics is held by insiders.Percentage Held by Institutions86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bolt Biotherapeutics' insider trading history. Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BOLT Stock News HeadlinesBolt Biotherapeutics (NASDAQ:BOLT) Stock: Insider Coastlands Capital Lp Purchases 33,094 SharesNovember 19 at 5:56 AM | americanbankingnews.comBolt Biotherapeutics (NASDAQ:BOLT) Stock: Insider Coastlands Capital Lp Purchases 20,000 SharesNovember 18, 2026 | insidertrades.comYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.November 22 at 1:00 AM | Profits Run (Ad)Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 14, 2026 | marketscreener.comMBolt Biotherapeutics, Inc. (NASDAQ:BOLT) Stock Short Interest Report for OctoberNovember 13, 2026 | americanbankingnews.comBolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 12, 2026 | globenewswire.comBolt Biotherapeutics (NASDAQ:BOLT) Major Shareholder Purchases 50,000 Shares of Company StockNovember 11, 2026 | insidertrades.comINVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?November 4, 2026 | globenewswire.comSee More Headlines BOLT Stock Analysis - Frequently Asked Questions How have BOLT shares performed this year? Bolt Biotherapeutics' stock was trading at $5.47 at the beginning of 2026. Since then, BOLT stock has decreased by 10.2% and is now trading at $4.91. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) issued its earnings results on Thursday, November, 12th. The company reported ($2.25) EPS for the quarter, beating analysts' consensus estimates of ($3.68) by $1.43. The firm earned $450 thousand during the quarter, compared to the consensus estimate of $450 thousand. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative trailing twelve-month return on equity of 154.11%. When did Bolt Biotherapeutics' stock split? Bolt Biotherapeutics's stock reverse split on the morning of Monday, June 9th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Bolt Biotherapeutics IPO? Bolt Biotherapeutics (BOLT) raised $213 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 11,500,000 shares at a price of $18.00-$19.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include onsemi (ON), Enterprise Products Partners (EPD), NIO (NIO), Energy Transfer (ET), Achilles Therapeutics (ACHL), Aldeyra Therapeutics (ALDX) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/12/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BOLT's financial health is in the Green zone, according to TradeSmith. BOLT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLT CIK1641281 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees23Year Founded2015Price Target and Rating Average Price Target for Bolt Biotherapeutics$14.50 High Price Target$22.00 Low Price Target$7.00 Potential Upside/Downside+195.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($14.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.38 million Net Margins-611.47% Pretax Margin-1,027.93% Return on Equity-154.11% Return on Assets-57.59% Debt Debt-to-Equity Ratio2.06 Current Ratio2.05 Quick Ratio2.61 Sales & Book Value Annual Sales$7.70 million Price / Sales1.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book1.50Miscellaneous Outstanding Shares2,610,000Free Float2,363,000Market Cap$12.82 million OptionableNot Optionable Beta0.85 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:BOLT) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredGold Miners Post Record Cash Flows as AI Stocks WobbleGold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.